Stryker Corp., US8636671013

Stryker stock gains 1.19% to EUR 293.00 premarket

Published on 11/19/2026 at 08:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker develops medical technology for hospitals and physicians, with orthopaedics among its core businesses. On Xetra, the stock closed at EUR 289.55 on Wednesday, November 18, 2026.

Key points for Stryker investors

  • Stryker reported third-quarter revenue of USD 6.52 billion and adjusted earnings per share of USD 3.52 on October 29, 2026.
  • Management expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of USD 14.80 to USD 14.90.
  • Slower hip and knee procedures remain a central operating issue, while MedSurg and Neurotechnology continue to support growth.
Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker stock traded at 293.00 euros on Lang & Schwarz at 08:32 CET on Thursday, November 19, 2026, 1.19 percent above the Xetra close of Wednesday, November 18, at 289.55 euros.

The medical technology company supplies products and systems for orthopaedics, surgery, neurotechnology and related hospital care. Its portfolio gives investors exposure to several healthcare markets, but joint-reconstruction demand remains an important focus.

Quarterly growth meets softer joint demand

Stryker reported third-quarter revenue of USD 6.52 billion on October 29, 2026, up 7.7% year over year, according to AlgovestIQ. Adjusted earnings per share rose 10.3% to USD 3.52, while reported earnings per share fell to USD 1.96 after a USD 293 million goodwill impairment and other special charges.

MedSurg and Neurotechnology revenue increased 9.2% to USD 3.7 billion, but Orthopaedics grew 5.7% to USD 2.9 billion. Hip and knee procedure trends were weaker, and management cited execution challenges affecting product adoption and commercial conversions.

On November 11, 2026, Stryker lowered its full-year outlook to organic sales growth of 6.5% to 7.0% and adjusted earnings per share of USD 14.80 to USD 14.90. Management expects fourth-quarter organic growth to be similar to the 7.7% achieved in the third quarter, assuming current hip and knee conditions persist, vascular supply constraints ease and capital demand remains strong.

For investors, the main issue is whether diversified businesses can offset slower joint-replacement demand. Margin expansion and cost discipline supported adjusted earnings in the third quarter, while continued weakness in hips and knees would keep execution and procedure volumes in focus.

Healthcare shares are also tracked through the S&P 500.

More news and analyses on Stryker stock.

Disclaimer...
en | US8636671013 | STRYKER CORP. | boerse | 70534485 | bgmi